Pneumocystis Pneumonia in Human Immunodeficiency Virus-infected Adults and Adolescents: Current Concepts and Future Directions

Overview

Journal Clin Med Insights Circ Respir Pulm Med

Publisher Sage Publications

Date 2015 Sep 2

PMID 26327786

Citations 24

Authors

Sadatomo Tasaka

Affiliations

Soon will be listed here.

Abstract

Pneumocystis jirovecii pneumonia (PCP) is one of the most common opportunistic infections in human immunodeficiency virus-infected adults. Colonization of Pneumocystis is highly prevalent among the general population and could be associated with the transmission and development of PCP in immunocompromised individuals. Although the microscopic demonstration of the organisms in respiratory specimens is still the golden standard of its diagnosis, polymerase chain reaction has been shown to have a high sensitivity, detecting Pneumocystis DNA in induced sputum or oropharyngeal wash. Serum β-D-glucan is useful as an adjunctive tool for the diagnosis of PCP. High-resolution computed tomography, which typically shows diffuse ground-glass opacities, is informative for the evaluation of immunocompromised patients with suspected PCP and normal chest radiography. Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line agent for the treatment of mild to severe PCP, although it is often complicated with various side effects. Since TMP-SMX is widely used for the prophylaxis, the putative drug resistance is an emerging concern.

Citing Articles

Risk of Pneumonia in Patients With HIV in Taiwan: Evidence from a Cross-sectional Study.

Wang J, Huang K, Tai C, Gau S, Tsai T, Wu C In Vivo. 2025; 39(2):1054-1066.

PMID: 40010982 PMC: 11884483. DOI: 10.21873/invivo.13910.

Breakthrough Pneumocystis jirovecii Pneumonia in an Allogeneic Hematopoietic Stem Cell Transplant Recipient.

Zieneldien T, Kim J, Greene J Cureus. 2024; 16(6):e61890.

PMID: 38978902 PMC: 11228424. DOI: 10.7759/cureus.61890.

Pneumocystis Pneumonia in Locally Advanced Breast Cancer Despite Prophylactic Use of Trimethoprim-Sulfamethoxazole During Prednisolone Treatment for a Pembrolizumab-Induced Immune-Related Adverse Event: A Case Report.

Kaneda Y, Gonda K, Asakura T, Wada M, Sawano T, Kurokawa T Cureus. 2024; 16(3):e56868.

PMID: 38659518 PMC: 11040520. DOI: 10.7759/cureus.56868.

Pneumocystis jirovecii pneumonia: a case report.

Gri J, Jain V J Med Case Rep. 2024; 18(1):52.

PMID: 38342895 PMC: 10860319. DOI: 10.1186/s13256-024-04350-4.

Study on the Prevalence of as a Causative Agent of Lung Pathology in People with Different Immune Status.

Harizanov R, Tsvetkova N, Ivanova A, Enikova R, Videnova M, Rainova I Biomedicines. 2023; 11(7).

PMID: 37509491 PMC: 10376562. DOI: 10.3390/biomedicines11071851.

References

Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R . Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis. 2009; 41(11-12):862-8. DOI: 10.3109/00365540903214256. View

Huang L, Morris A, Limper A, Beck J . An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP). Proc Am Thorac Soc. 2006; 3(8):655-64. DOI: 10.1513/pats.200602-015MS. View

Tu G, Ju M, Xu M, Rong R, He Y, Xue Z . Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients. Nephrology (Carlton). 2014; 18(11):736-42. DOI: 10.1111/nep.12133. View

Morris A, Ben Beard C, Huang L . Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect. 2002; 4(1):95-103. DOI: 10.1016/s1286-4579(01)01514-3. View

Pifer L, Hughes W, Stagno S, Woods D . Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978; 61(1):35-41. View

Crothers K, Beard C, Turner J, Groner G, Fox M, Morris A . Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS. 2005; 19(8):801-5. DOI: 10.1097/01.aids.0000168974.67090.70. View

Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P . Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?. Clin Infect Dis. 2010; 51(5):611-9. DOI: 10.1086/655761. View

Fujii T, Nakamura T, Iwamoto A . Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother. 2007; 13(1):1-7. DOI: 10.1007/s10156-006-0484-5. View

Koziel H, Eichbaum Q, Kruskal B, Pinkston P, Rogers R, Armstrong M . Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest. 1998; 102(7):1332-44. PMC: 508980. DOI: 10.1172/JCI560. View

10.

Kovacs J, Masur H . Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009; 301(24):2578-85. DOI: 10.1001/jama.2009.880. View

11.

Limper A, Offord K, Smith T, Martin 2nd W . Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989; 140(5):1204-9. DOI: 10.1164/ajrccm/140.5.1204. View

12.

Navin T, Beard C, Huang L, Del Rio C, Lee S, Pieniazek N . Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study. Lancet. 2001; 358(9281):545-9. DOI: 10.1016/S0140-6736(01)05705-1. View

13.

Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C . Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009; 4(5):e5575. PMC: 2680972. DOI: 10.1371/journal.pone.0005575. View

14.

Quist J, Hill A . Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest. 1995; 108(2):415-8. DOI: 10.1378/chest.108.2.415. View

15.

Cisse O, Pagni M, Hauser P . De novo assembly of the Pneumocystis jirovecii genome from a single bronchoalveolar lavage fluid specimen from a patient. mBio. 2012; 4(1):e00428-12. PMC: 3531804. DOI: 10.1128/mBio.00428-12. View

16.

Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser P . Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004; 48(11):4301-5. PMC: 525445. DOI: 10.1128/AAC.48.11.4301-4305.2004. View

17.

Vassallo R, Standing J, Limper A . Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol. 2000; 164(7):3755-63. DOI: 10.4049/jimmunol.164.7.3755. View

18.

Hughes W, Leoung G, Kramer F, Bozzette S, Safrin S, Frame P . Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993; 328(21):1521-7. DOI: 10.1056/NEJM199305273282103. View

19.

Arcenas R, Uhl J, Buckwalter S, Limper A, Crino D, Roberts G . A real-time polymerase chain reaction assay for detection of Pneumocystis from bronchoalveolar lavage fluid. Diagn Microbiol Infect Dis. 2006; 54(3):169-75. DOI: 10.1016/j.diagmicrobio.2005.08.006. View

20.

Dieterich D, Lew E, Bacon D, Pearlman K, Scholes J . Gastrointestinal pneumocystosis in HIV-infected patients on aerosolized pentamidine: report of five cases and literature review. Am J Gastroenterol. 1992; 87(12):1763-70. View